Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
..drivel and pump and dumpers aside, Verici looks set to pick up testing momentum heading into the second half, as sales via Thermo Fischer are scheduled to get underway during Q2. I would expect a fair bit of news flow around the start of that process and assuming sales go well then perhaps the shares can move to recover their IPO price of 20p and build further from there.
Regarding potential testing volumes, there were reportedly ~25k kidney transplants in the US in 2022 and the company usually references an annual number of 20k for the US, conducted across the 200 or so kidney transplant centres.
"In 2022, a record 25,498 kidney transplants were performed in the US, according to the United Network for Organ Sharing (UNOS)."
Assuming Thermo Fischer has full coverage of the kidney transplant centres and a steady adoption of the Verici testing suite, would it be cautious to estimate 1-3% in their first year, so 250-750 transplants? How many tests per transplant, 1-3? So an initial guide range of 250-2250 tests at $2,650 per test? This implies a gross revenue range of $663k to £$6m at full rate.
Thinking further ahead let's assume they achieve a market share of say 15% in Year 2 and maybe a bullish 30% in Year 3... Again, assuming a testing rate per transplant of 1-3 then this implies a revenue range of $10m-$30m for Year 2 and $20m-$60m for Year 3.
I have no clue if any of this is possible, or realistic, but what I like about it is the low end numbers easily underpin the current valuation and therefore any positive surprise to this suggests plenty of upside and who knows what level of activity and testing adoption rates lead to Thermo Fischer progressing their relationship with Verici to a full acquisition/take over?
Net net, 10-11p or market cap of £18m (no debt and £5m+ cash) looks like a good opportunity to me!
Nb, I have been a holder since they IPO'd back in 2020, sold a few into the spike around 60-80p and have been steadily buying those back and more over the past year.
GLA and DYOR!
Yawn... I'm falling asleep listening to your drivel.
Today's rns is a fantastic opportunity to buy vrci. and the fact sp not moved gives me to load up at these bargain SP
Thermo Fisher are not stupid..... they have world class researchers at their disposable who decided to partner with VRCI.
market makers are asleep in this
Based on the muppet numbers....
PE of 10 requires £1.9m of annual profit to sustain the current share price. That would be less than 3p a test for capturing the whole market of 69.3m patients. Plenty of upside then
69m medicare clients ya muppettito are they all needing a kidney transplant!!!!
Today's bagger?
let this sink in....
With 63.9 m patients
per tests $2650 that's 169 billion market
Mcap only £19m
Earl pee aff wae yer drivel man.
I love that the go to is always "wait until US investors wake up"... nothing ever happens.
Let USA investors wake up to this news
Already Partnership with Thermo Fisher (multi billion dollars company)
bargain SP
With 63.9 m patients
per tests $2650 that's 169 billion market
Mcap only £19m💥
#vrci
I feel this will rise when markets wakes up to this news
Fund managers will be buying these at cheap prices
Nah . I think beware of people trying to give advice about other posters .
Oh dear EarlofAim, how many stocks you and Ria20 P&D and the newbies left holding the baby?
Beware of people who give you stock tips with random price targets. They are likely pump-and-dumpers who are trying to offload their shares at a higher price. Newbies often fall for this scam and end up losing money.
EarlofAim Twitter accounts:
Equity-Trader - https://twitter.com/EquityTrader888
Investology - https://twitter.com/Profitprofit1
Check for yourself how many pump-and-dump posts he posts every day and back it up with his LSE posts to scam investors.
Pumpers really trying harder now. lol bless them
Medicare National Payment Rate for Tutivia? and Clarava? Effective as of January 1, 2024
CMS finalises gapfill median rate at $2,650 per test
Mcap only £19m
cash c£6m
this is the beginning of something special here
Wow!!
$2650 per test and X 63.9m is $169 billion market to be fulfilled by the likes of VRCI
this is huge potential to become mid tier company
Medicare National Payment Rate for Tutivia? and Clarava? Effective as of January 1, 2024
CMS finalises gapfill median rate at $2,650 per test
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule ("CLFS") payment rate of $2,650 established through the "gapfill" process for both Tutivia? (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava? (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.
Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients.
Great news. Great to see the payment rates confirmed. The consistent positive updates are building a solid platform. VRCI has to be on the radar for a big player to come in
Two great rns what a Monday morning . Great work team Verici dx .
Remember Clarava and Tutivia are now both in the market as real products and with Thermos sales team driving sales 2024 is looking amazing.
Pharma is coming back into favour.Verici has best in class products and iam sure Thermo will take it out this year ,climb aboard now.
That's the kind of thing you type as you press sell for 20k lol
This is getting ready to pop ,great value here totally undervalued .3great products 1st in class and one of the worlds largest pharmas backing to boot just a matter of patience.
Thermo fisher will be looking over the numbers as we speak.Buyout sooner rather than later nailed on.
What is the source please?
GL.